• SEC Filings

MYRIAD GENETICS, INC. (NASDAQ:MYGN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) On November 29, 2018, at our annual meeting of stockholders, our stockholders approved an amendment to our 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”), to increase the number of shares of common stock available for grant of awards under the 2017 Plan by an additional 1,000,000 shares. A description of the material features of the 2017 Plan and related matters are set forth in our definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 10, 2018, under the heading “Proposal 2: Approval of the Amendment to Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan,” and is incorporated herein by reference. Such description is qualified in its entirety by reference to the actual terms of the 2017 Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

ITEM 5.07Submissions of Matters to a Vote of Security Holders

(a)On November 29, 2018, we held our 2018 Annual Meeting of Stockholders (“the Annual Meeting”).Of the 74,715,671 shares of common stock outstanding as of the record date of October 2, 2018, a quorum of 66,719,746 shares, or approximately 89.29% of the eligible shares, was present in person or represented by proxy.

(b)The following is a brief description of each matter submitted to a vote at the Annual Meeting, as well as the number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter.

Proposal No. 1: Elect Directors

To elect John T. Henderson, M.D. and S. Louise Phanstiel to serve until the 2021 Annual Meeting of Stockholders, and until their successors are duly elected and qualified or until their earlier death, resignation, retirement or removal.

Proposal No. 2: Approval to Amend our 2017 Employee, Director and consultant Equity Incentive Plan

To approve an amendment of our 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, to increase the aggregate number of shares of common stock available for the grant of awards by an additional 1,000,000 shares.

Proposal No. 3: Independent Public Accountants

Proposal No. 4: Proposal, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement

Page 2

ITEM 9.01Financial Statements and Exhibits.

(d) Exhibits

(+)Management contract or compensatory plan arrangement

Page 3

MYRIAD GENETICS INC Exhibit
EX-10.1 2 mygn-ex101_10.htm EX-10.1 2017 EMPLOYEE,…
To view the full exhibit click here

About MYRIAD GENETICS, INC. (NASDAQ:MYGN)

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.